Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Media Contact

Stephen Schultz
VP Investor Relations (U.S.)
T: 917-280-2424 / 401 500 6570

Recent Press Releases

May 26, 2011
Barcelona, Spain and Porton Down, UK; 26th May 2011: Almirall, S.A.
May 17, 2011
Porton Down, UK, 17 May 2011: GW Pharmaceuticals plc (AIM: GWP, “GW” or “the Group”), the specialty pharmaceutical company focused on cannabinoid science, announces its interim results for the six m
Apr 20, 2011
Porton Down, UK; 20 April 2011: GW Pharmaceuticals plc (AIM: GWP) today announces that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent which protects the
Apr 15, 2011
Porton Down, UK; 15 April 2011: GW Pharmaceuticals plc (AIM:GWP) today announces that Sativex® oromucosal spray has been approved in the Czech Republic as a treatment for spasticity due to Multiple
Apr 11, 2011
Under the terms of the agreement, Novartis will have exclusive commercialisation rights to Sativex®and will also be responsible for regulatory filings and act as Marketing Authorisation holder for Sativex®.
Mar 22, 2011
- National approvals expected in Germany, Italy, Denmark, Sweden, Austria and Czech Republic from mid-2011 onwards -
Mar 14, 2011
- Under the terms of its licence agreement with Almirall, GW will now receive a £2.5m milestone payment in respect of the commercial launch of Sativex®in Spain -  
Mar 02, 2011
Porton Down, UK, 2 March 2011: GW Pharmaceuticals (AIM: GWP) announces that positive results from a Phase III clinical study of Sativex® Oromucosal Spray (delta-9-tetrahydrocannabinol (THC) and cann
Feb 17, 2011
Porton Down, UK, 17 February 2011: GW Pharmaceuticals (AIM: GWP) is pleased to announce that Sativex® has been granted national reimbursement in Spain from the Spanish Ministry of Health.
Jan 17, 2011
Porton Down, UK; 17 January 2011: GW Pharmaceuticals plc (AIM: GWP) confirms that following its announcement on 23 November 2010 that the Phase III clinical trials programme of Sativex® in cancer pa